◾ Type 2 diabetes mellitus (T2DM) is an important public health concern. Based on World Health Organization (WHO) estimates, the number of people with T2DM is projected to reach over 350 million throughout the world by 2030 1 ◾ In France, there are 2.9 million people with diabetes (4.4% of the total population), of which T2DM accounts for 92%. 2 T2DM contributes to early mortality and high morbidity in the persons affected, and has become a constant burden for the resources of the French health care system 3 ◾ Canagliflozin (CANA) is a novel, oral antihyperglycaemic agent (AHA) with sodium glucose co-transporter 2 (SGLT2) inhibition activity developed for the treatment of adults with T2DM 4-15 ; CANA was approved for use in the European Union in November 2013
Treatments Compared
◾ This study compared treatment with CANA 100 or 300 mg per day to LIRA 1.2 or 1.8 mg per day ◾ Since both LIRA 1.2 and 1.8 mg are used in French clinical practice, the results shown are weighted by the market share of these doses in France: 62% and 38% for LIRA 1.2 and 1.8 mg, respectively 21 ◾ Patients remained on the initial treatment until their HbA1c level was above 7.5%, at which point they switched to insulin 40 IU/day (the WHO-defined daily dose)
Clinical Inputs
◾ The clinical trial programme data for CANA were used as the primary source of treatment effects (DIA3002 and DIA3015; Table 1 ) 7,13 ◾ A systematic review and network meta-analysis (NMA) of agents used in combination with MET plus SU were used to supplement the clinical inputs where necessary (Pacou et al 22 and data on file). However, no studies of LIRA 1.2 mg in combination with MET plus SU were found ◾ The NMA estimated that, in combination with MET alone, LIRA 1.2 mg was associated with 0.15% less effect on HbA1c, 0.19 mmHg more effect on systolic BP (SBP), and 0.31 kg less weight gain than LIRA 1.8 mg. These differences were added to the treatment effects for LIRA 1.8 mg in combination with MET plus SU to estimate treatment effects for LIRA 1.2 mg ◾ To test whether model findings were robust to the treatment effects for LIRA 1.2 mg, scenario analyses were performed using different time points in the dual therapy NMA and assuming a multiplicative rather than additive dose-response relationship ◾ The multiplicative method used the ratio of the LIRA 1.2 mg treatment effect to the LIRA 1.8 mg treatment effect.
In order to determine the relative treatment effect on HbA1c for CANA 100 mg versus LIRA 1.2 mg in triple therapy (add-on to MET + SU), the relative treatment effect for CANA 100 mg versus LIRA 1.8 mg was derived from triple therapy (add-on to MET + SU) and multiplied by the ratio of the relative treatment effects for CANA 100 mg versus LIRA 1.2 mg in dual therapy (add-on to MET). This scenario was performed for both 26-and 52-week data to investigate the robustness of the base case results ◾ HbA1c and SBP progressed for each patient according to UKPDS 68. 23 Lipid values progressed according to the equations from the Framingham Heart Study. 24 Body mass index (BMI) did not change over time, apart from the impact on weight from the drug treatment. The treatment effects on lipids and BMI were reversed when patients switched to insulin ◾ AEs included in the model were urinary tract infections and genital mycotic infections. Conservatively, no AEs thought to be associated with GLP-1 agonists (eg, nausea) were included in the model -In the CANA studies, rates of urinary tract infections were generally similar across groups; there was a higher incidence of genital mycotic infections with CANA versus comparator treatments ◾ Hypoglycaemia events were included as severe and non-severe in the model ◾ Non-diabetes-related mortality was included in the model using data from the WHO and the CépiDc. 25, 26 These data included all causes of mortality, and were adjusted by removing mortality caused by diseases explicitly modelled in the CDM
Economic Inputs
◾ The key costs used in the model are shown in Table 2 . The public prices of drugs were specified as those relevant to the French National Authority for Health (Haute Autorité de Santé [HAS]). The costs for MET and SU came from the French Type 2 Diabetes Guidelines (DT2; January 2013). Other costs were obtained from a number of local data sources [27] [28] [29] ◾ CDM default utility values were used. As recommended by HAS, an annual discount rate of 4% was applied for costs and health effects. 27 The time horizon used for the economic evaluation was 40 years, to approximate a lifelong time horizon
RESULTS
◾ The base case results are shown in Table 3 . CANA 300 mg was found to be associated with lower costs and improved outcomes compared to LIRA; however, incremental quality-adjusted life years (QALYs) and incremental life years (LYs) were small. This suggests that CANA 300 mg and LIRA are very similar in terms of clinical outcomes, with CANA 300 mg being substantially cheaper, thereby generating substantial cost savings ◾ CANA 100 mg was associated with lower QALYs; however, there were substantial cost savings of €1,388 per patient ◾ One-way sensitivity analyses were performed using the lower and upper credibility intervals (Crl) from the NMA for the treatment effects associated with LIRA 1.2 mg ◾ A number of scenario analyses were performed. All scenario and sensitivity analyses are shown in the tornado diagrams in Figure 1 ◾ Of the sensitivities/scenarios considered, reducing the discount rate to 0%, increasing the HbA1c switching threshold from 7.5% to 8.0%, and varying the HbA1c treatment effect of LIRA 1.2 mg using the lower and upper credibility intervals were found to have the largest effects on incremental costs and incremental QALYs ◾ A probabilistic sensitivity analysis (PSA) was also performed. 22 and data on file) in combination with MET + SU. § Treatment effect for LIRA 1.8 mg adjusted less treatment effect difference in dual therapy NMA. Treatment effect from DIA3015. 13 ¶ Treatment effect from DIA3015 and NMA (Pacou et al 22 and data on file) in combination with MET + SU. # Treatment effect for LIRA 1.8 mg adjusted less treatment effect difference in dual therapy NMA. **Weight was converted to BMI assuming an average height of 1.67 m. † †Not available in the NMA, assumed to be the same as CANA. 
Acute events
Severe hypoglycaemia 4,525 35 Non-severe hypoglycaemia (assumed) 0 MI, myocardial infarction; CHF, congestive heart failure.
Eye disease Cost (2013 €)
Laser treatment 222 28 Cataract operation 1,567 29 Following cataract operation 37 28 Blindness CANA 300 mg vs LIRA 
